Clinical trials: Sitagliptin, completed
Diabetes
Replication of the GRADE Diabetes Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05099198
- Testing
- Sitagliptin, Glimepiride
- Where
- United States
- Volunteers
- 6,403 people
- Sponsor
- Brigham and Women's Hospital
Metabolic Syndrome, Hypertension
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome.
- Trial name
- NCT00666848
- Testing
- Enalapril 5mg, Enalapril 10mg, Sitagliptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Healthy
Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses.
- Trial name
- NCT02172196
- Testing
- BI 10773, Sitagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)
Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to determine the bioequivalence of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck…
- Trial name
- NCT05798715
- Testing
- Gleptomet 50/1000(Metformin HCl & Sitagliptin), Janumet 50/1000(Metformin HCl & Sitagliptin)
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Type 2 Diabetes
Effects of Glutamine on GLP-1 and Insulin Secretion in Man
This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.
- Trial name
- NCT00673894
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 22 people
- Sponsor
- Garvan Institute of Medical Research
Type 1 Diabetes
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
The purpose of this study is to see if the use of metformin and sitagliptin used in conjunction with insulin can improve the blood sugars of teenagers with Type 1 diabetes.
- Trial name
- NCT01718093
- Testing
- Sitagliptin, Metformin, Sitagliptin + Metformin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Type 2 Diabetes
Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2 diabetes.
- Trial name
- NCT01901861
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Lund University
Type 2 Diabetes Mellitus
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
This is a randomized, double-blind, active control, parallel group, exploratory phase 4 study to compare the effect of teneligliptin versus sitagliptin on glucose variability when added on to metformin in patients with…
- Trial name
- NCT02512523
- Testing
- Teneligliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Handok Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes…
- Trial name
- PIONEER 7 (NCT02849080)
- Testing
- semaglutide, sitagliptin
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 504 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02318693
- Testing
- Sitagliptin, Glibenclamide
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Patients
Drug Interaction Study Between Dorzagliatin and Sitagliptin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM.
- Trial name
- NCT03790839
- Testing
- Sitagliptin, Dorzagliatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hua Medicine Limited
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00094757
- Testing
- Comparator: sitagliptin 100 mg, Comparator: sitagliptin 200 mg, Comparator: pioglitazone
- Volunteers
- 521 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT06659744
- Testing
- New use of semaglutide injection, New initiation of sitagliptin
- Where
- United States
- Volunteers
- 158,310 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type 2 Diabetes, Cardiovascular Risk
Canagliflozin and Myocardial Fibrosis
Recently, large clinical intervention studies have demonstrated the cardiovascular protective effects on of sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin, dapagliflozin, and canagliflozin in reduction…
- Trial name
- CANA-DIA-FIB (NCT05367063)
- Testing
- Canagliflozin 100mg or Sitagliptin 100mg
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05236998
- Testing
- SID1903 (FDC), Dapagliflozin and Sitagliptin
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Diabetes Mellitus, Type 2, Urosepsis
Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
The purpose of this study is to compare the risk of serious adverse events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
- Trial name
- NCT04017221
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Other treatment combinations
- Where
- Canada
- Volunteers
- 1,249,636 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Diabetes Mellitus, Type 2
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq.
- Trial name
- NCT07531108
- Testing
- Empagliflozin-Metformin, Sitagliptin-Metformin, Metformin
- Where
- Iraq
- Volunteers
- 186 people
- Sponsor
- Hawler Medical University
Healthy Volunteers
The Role of Phosphodiesterase Inhibitors in Incretin Secretion
Background: The drug Roflumilast (Daliresp) is used to treat Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it difficult to breathe.
- Trial name
- NCT02363335
- Testing
- Roflumilast/Sitagliptin, Sitagliptin, Roflumilast
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute on Aging (NIA)
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc